Details:
Under the agreement, SciClone will pursue the development and registration of Orserdu (elacestrant), a once-daily oral endocrine monotherapy, for the treatment of postmenopausal women or adult men, in China and commercialize Orserdu upon its regulatory approval in China.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: SciClone Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 07, 2023
Details:
Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with ER‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: European Organisation for Research and Treatment of Cancer
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
ELZONRIS® (tagraxofusp), a recombinant protein is the only approved treatment for patients with blastic plasmacytoid dendritic cell neoplasm, and the first and only approved CD123-targeted therapy, in both the United States and Europe.
Lead Product(s): Tagraxofusp
Therapeutic Area: Oncology Product Name: Elzonris
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Nippon Shinyaku
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with ER‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2023
Details:
Ceplene® demonstrated a clinical interest in maintenance treatment of acute myeloid leukemia (AML) in patients below 60 years of age in first "complete remission" (symptom-free period of disease after initial treatment) in a clinical study.
Lead Product(s): Histamine Dihydrochloride,Interleukin 2
Therapeutic Area: Oncology Product Name: Ceplene
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Delbert Lab
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 18, 2022
Details:
Eligard® is a marketed medicinal product for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Oncology Product Name: Eligard
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Tolmar
Deal Size: $168.6 million Upfront Cash: $42.1 million
Deal Type: Licensing Agreement January 29, 2021
Details:
ELZONRIS is the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, in Europe. Approval is based on the results of the largest prospective clinical trial ever conducted in patients with treatment-naïve or previously-treated BPDCN.
Lead Product(s): Tagraxofusp
Therapeutic Area: Oncology Product Name: Elzonris
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2021